RO5190591/Danoprevir
Drug timelines are a Plus or Pro feature.
1 regulatory and trial event tracked for RO5190591/Danoprevir, covering 2016-11-02 to 2016-11-02. Get the full timeline:
Most recent: Clinical Trial Update: A Study of Combination Treatment With an HCV Polymerase Inhibitor (RO5024048) and an HCV Protease Inhibitor (RO5190591/Danoprevir) in Genotype 1 Chronic Hepatitis C Patients [Phase 1]